Oppenheimer downgrades Chemed's target price to $580

Summary

Oppenheimer has lowered its price target for Chemed (NYSE:CHE) from $650.00 to $580.00 while maintaining an ‘outperform’ rating. This new target suggests a potential upside of 38.05% from the current price. Other analysts have also adjusted their ratings, with Jefferies setting a $500.00 target and Royal Bank of Canada adjusting theirs to $640.00. Chemed’s stock opened at $420.15, with a one-year high of $623.60. The company reported a quarterly EPS of $4.27, missing estimates, and has a market cap of $6.15 billion.Market Beat

Impact Analysis

The event is classified as a company-level event as it specifically impacts Chemed Corporation. The adjustment of Chemed’s target stock price by Oppenheimer from $650 to $580 may influence investor sentiment and Chemed’s market perception. This decision was likely driven by Chemed’s recent performance, including missing EPS estimates and a decline in EBITDA by 18.7%Reuters. Despite this, Oppenheimer maintains an ‘outperform’ rating, indicating confidence in Chemed’s potential for recovery and growth. Other analysts, such as Jefferies and the Royal Bank of Canada, have also revised their targets, reflecting a broader reassessment of Chemed’s market positionMarket Beat+ 2. The mixed analyst sentiment suggests potential volatility and varying investor interpretations of Chemed’s financial health. Investment opportunities may exist for value-oriented investors seeking to capitalize on perceived undervaluation, given the significant potential upside from the current priceMarket Beat. However, risks include further earnings underperformance and continued profitability challenges.